2C-T-36

2C-T-36, also known as 2C-T-TFM, 2,5-dimethoxy-4-(trifluoromethylsulfanyl)phenethylamine, or CYB210010, is a psychedelic drug of the phenethylamine and 2C families related to other psychedelics such as 2C-TFM, 2C-T, and 2C-T-21 (2C-T-FE).

Alexander Shulgin attempted to synthesise this compound in the 1990s, and mentions it in his book PiHKAL (Phenethylamines I Have Known and Loved) under the entry for 2C-T-21, but was unsuccessful in producing a key intermediate and never assigned it a 2C-T number. This compound was ultimately first synthesised by Geoffrey Varty and colleagues at Irish biopharmaceutical company Helus Pharma (formerly Cybin) in 2023.

It has a K_i of 0.35 nM at the serotonin 5-HT_2A receptor, and an EC₅₀Tooltip half-maximal effective concentration of 4.1 nM at the serotonin 5-HT_2A receptor and 7.3 nM at the serotonin 5-HT_2C receptor, compared to 88 nM at the serotonin 5-HT_2B receptor. It is a potent, selective, long acting, and orally active agonist for the serotonin 5-HT_2A and 5-HT_2C receptors and produces psychedelic-like responding in several different animal species. The interactions of 2C-T-36 with numerous other receptors and targets have also been described. It has only been studied preclinically as of 2024 and is not known to have been tested in humans.

It is a controlled substance in Canada under phenethylamine blanket-ban language. The drug is not an explicitly controlled substance in the United States.

Related drugs include the deuterated phenethylamine HLP005 (CYB005) and the deuterated substituted tryptamines HLP003 (CYB003) and HLP004 (CYB004).